Growth Hormone
Phase 2Recruiting 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
TBI (Traumatic Brain Injury)
Conditions
TBI (Traumatic Brain Injury), Concussion, Brain, Sport Injury, Anterior Pituitary Hyposecretion Syndrome, Hypopituitarism, Growth Hormone Deficiency
Trial Timeline
Oct 8, 2019 → Sep 1, 2026
NCT ID
NCT04121780About Growth Hormone
Growth Hormone is a phase 2 stage product being developed by Novo Nordisk for TBI (Traumatic Brain Injury). The current trial status is recruiting. This product is registered under clinical trial identifier NCT04121780. Target conditions include TBI (Traumatic Brain Injury), Concussion, Brain, Sport Injury.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04121780 | Phase 2 | Recruiting |
| NCT03225755 | Pre-clinical | Completed |
| NCT00568568 | Pre-clinical | Completed |
| NCT00187993 | Pre-clinical | UNKNOWN |